Sage Journals: Discover world-class research

Abstract

Background:

Despite significant achievements in healthcare quality improvement for ischemic stroke and transient ischemic attack (TIA), the advancements and challenges of patient adherence to secondary prevention medications remain unclear.

Objectives:

We aimed to investigate adherence rates of secondary prevention medication and identified the key determinants in Chinese patients with ischemic stroke or TIA.

Design:

This is an observational study.

Methods:

Using the China National Stroke Registry (CNSR) database from 2007 to 2018, this observational study included patients with ischemic stroke or TIA who were admitted to the hospital within 7 days of symptom onset. The study outcome was the patient adherence to secondary prevention medications, which was defined as the consistent use of prescribed antithrombotic, lipid-modulating, antidiabetic, and antihypertensive medications post-discharge using an “all-or-none” approach. We calculated adherence rates in 3 and 12 months. Logistic regression models were used to evaluate influencing factor patterns and challenges in the improvement of patient adherence.

Results:

A total of 12,873 patients from CNSR I and 15,099 patients from CNSR III were included. Patient adherence rates for secondary prevention medications increased from 66.97% in CNSR I to 80.76% in CNSR III (p < 0.0001) in 3 months, and from 35.08% to 59.81% (p < 0.0001) in 12 months. Patient age, the National Institute of Health stroke scale score at admission, disease diagnosis, the Trial of Org 10172 in Acute Stroke Treatment classification, family income per capita, alcohol consumption, dyslipidemia history, hypertension history, diabetes history, and heart disease history appeared to exhibit a significant association with adherence.

Conclusion:

In spite of the remarkable progress in patient adherence to secondary prevention of stroke from 2007 to 2018, challenges remain in sustaining quality improvement initiatives, necessitating further improvements by addressing disease severity, lifestyle, medical history, and socioeconomic factors.

Keywords

ischemic stroke patient adherence secondary prevention transient ischemic attack

Introduction

Ischemic stroke, accounting for the majority of stroke cases, not only inflicts immediate neurological deficits but also carries a substantial risk of recurrence, which can lead to severe consequences for individuals and their families.^1–3 Transient ischemic attack (TIA) is a temporary disruption of blood flow to the brain that causes short-lived neurological symptoms, serving as a warning sign for potential future stroke.^4,5 The growing recognition of stroke recurrence as a critical public health concern underscores the urgent need for effective prevention strategies to mitigate this risk and improve long-term outcomes for stroke survivors.^6–8 Secondary prevention of ischemic stroke and TIA is a cornerstone for reducing the likelihood of subsequent cerebrovascular events, managing these conditions, which typically involves a multifaceted pharmacological regimen tailored to address various risk factors, including antithrombotic, lipid-modulating, antidiabetic, and antihypertensive medications.^7,9,10

Despite the proven efficacy of secondary prevention medications, their success hinges largely on patient adherence to prescribed medications.^11,12 Nonadherence not only diminishes the potential benefits of these medications but also increases the risk of stroke recurrence, disability, and morbidity.¹³ Therefore, understanding patients’ adherence to secondary prevention medications and obstacles impeding adherence is pivotal in formulating targeted interventions and ultimately reducing stroke recurrence while enhancing patient outcomes.^14,15 While healthcare systems and providers have made strides in enhancing the quality of care and reducing the recurrence rate of stroke through continuous quality improvement initiatives in China, it remains unclear whether these measures have exerted any influence on perceptions and behaviors of patients with ischemic stroke or TIA.^16–18 In addition, the patterns of factors influencing patient adherence to secondary prevention medications and the existing challenges remain insufficiently understood.^19,20

To bridge this knowledge gap and advance quality improvement, this study investigated adherence rates of secondary prevention medications and identified the key determinants in patients with ischemic stroke or TIA, utilizing the China National Stroke Registries (CNSR I and III).

Methods

Data source and study population

The source population for the observational study was the entire population of the CNSR I and CNSR III, which are nationwide prospective registries of patients with acute cerebrovascular events used to evaluate healthcare quality. The CNSR I recruited 21,902 patients with acute cerebrovascular events within 14 days of the index event from 132 hospitals between September 2007 and August 2008. The CNSR III recruited 15,166 patients with ischemic stroke or TIA within 7 days of the symptom onset between August 2015 and March 2018. The comprehensive details have already been published elsewhere.^21,22 This study encompassed patients who were admitted to the hospital within 7 days of symptom onset and enrolled in the CNSR I or CNSR III, with a diagnosis of ischemic stroke or TIA. The diagnosis was made in accordance with the criteria set forth by the World Health Organization and confirmed by magnetic resonance imaging or brain computed tomography.^8,23 The study conformed to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines.²⁴

Outcomes

At 3 months post-enrollment, patients underwent face-to-face interviews, while at 6 and 12 months, trained research coordinators contacted them via telephone. During these interactions, data pertaining to adherence to prescribed secondary prevention medications, survival status, and instances of stroke recurrence were systematically collected. Verification of vascular events was obtained from the respective hospitals, whereas suspected cases of recurrent cerebrovascular events that did not result in hospitalization were evaluated by an independent endpoint adjudication committee. Stroke recurrence can manifest in various forms, including cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage.

The study outcome was the patient adherence to secondary prevention medications in 3 and 12 months using an “all-or-none” approach.²⁵ In this context, patients were deemed adherent solely when they consistently complied with all prescribed medications. Any deviation from this full adherence led to their classification as non-adherent. Specifically, 3-month adherence was defined as patient-reported consistent use of all discharge-prescribed antithrombotic (including antiplatelet agents and anticoagulants), lipid-modulating, antidiabetic, and antihypertensive medications at the 3-month follow-up assessment, while 12-month adherence indicated their continuous use of these medications during follow-up visits at 3, 6, and 12 months after enrollment. In the classification and definition of secondary prevention medications, we chose to use the term “antithrombotic agents” rather than classifying “antiplatelet agents” and “anticoagulants” as two separate categories, considering the dynamic nature of patients’ conditions and the corresponding adjustments required in antithrombotic strategies.^26,27 Furthermore, we chose to employ the term “lipid-modulating agents” rather than specifically “statins,” recognizing that some patients may switch to alternative medications due to intolerance to statins.^9,10

Variables

The study incorporated a series of key variables, including patient demographics such as age and gender, lifestyle factors including smoking (current or past) and alcohol consumption (current or past), and medical history encompassing previous stroke, TIA, dyslipidemia, diabetes, hypertension, and heart disease. In addition, final diagnosis (categorized as either ischemic stroke or TIA), the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification for ischemic stroke, and clinical severity upon admission, assessed using the National Institutes of Health Stroke Scale (NIHSS) score, were considered. We also included family income per capita, with thresholds set at 3000 Chinese yuan (CNY) for CNSR I and 2300 CNY for CNSR III monthly based on the information collection. Treatment modalities administered, including intravenous thrombolysis and endovascular therapy, were also included as variables in the analysis. Endovascular therapy refers to arterial thrombolysis, mechanical thrombectomy, or stent therapy, regardless of whether intravenous thrombolysis was administered.

Statistical analysis

We used descriptive statistics to characterize patient categories. Accordingly, baseline characteristics were presented as either the mean with standard deviations for normally distributed continuous variables or the median with interquartile range (IQR) for skewed continuous variables, while categorical variables were summarized by the number of patients with percentages. Regarding adherence, patients who were lost to follow-up or had incomplete adherence data were categorized as non-adherent. Regarding other variables, our analysis revealed no missing data. Patients who died during the corresponding follow-up period were excluded from the analysis owing to the inaccessibility of adherence data. During the study period from 2007–2008 (CNSR I) to 2015–2018 (CNSR III), the adherence rates to secondary prevention medications (including adherence rates for specific drug categories) and the recurrence rates of stroke in 3 and 12 months were calculated. Also, we calculated the prescription rates of secondary prevention medications for patients at discharge.

To investigate the influencing factor patterns of patient adherence within 3- and 12-month timeframes in 2007–2008 and 2015–2018, logistic regression analysis was performed, integrating the aforementioned variables, with odds ratios (OR) and corresponding 95% confidence intervals (CI) estimated. Furthermore, data from two registries were merged to form a unified dataset for further analysis, in which study period (CNSR I or CNSR III) and interaction terms of study period and covariates were additionally included in the logistic regression model. An interaction test was conducted to evaluate how the study period modified the associations between influencing factors and patient adherence. We also carried out sensitivity analyses to ensure the robustness of our findings. First, we classified patients with an adherence rate of 75% or above as adherent. To elaborate further, given the four medication categories that constituted our focus, a patient was considered adherent if they adhered to at least three of these categories. Second, in light of the potential bias stemming from categorizing patients lost to follow-up as non-adherent, we excluded such patients from our analysis.

To further elucidate the impact of these influencing factors on adherence, we integrated statistically significant factors derived from any database analysis into logistic regression models to explore their associations with adherence to the four drug categories (antithrombotic, lipid-modulating, antidiabetic, and antihypertensive medications) over the 3- and 12-month periods. Specifically, in our analysis of adherence over a 3-month period, we included four variables: age, NIHSS score at admission, final diagnosis, TOAST classification for ischemic stroke, family income per capita, history of diabetes, and history of heart disease. For the 12-month analysis, we incorporated the following variables: NIHSS score at admission, TOAST classification for ischemic stroke, family income per capita, alcohol consumption history, history of dyslipidemia, history of diabetes, and history of hypertension. All analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Inc.; Cary, NC, USA), and statistical significance was defined as a two-tailed p value of <0.05.

Results

Baseline characteristics

After excluding patients enrolled more than 7 days after symptom onset or with missing data of time from onset to enrollment, 12,873 patients (7917 (61.50%) were men; median (IQR) age, 67 (57–75) years; 11,757 ischemic stroke and 1116 TIA) from CNSR I and 15,099 patients (10,311 (68.29%) were men; median (IQR) age, 63 (54–70) years; 14,083 ischemic stroke and 1016 TIA) from CNSR III were included (Table 1, Supplemental Figure 1). Upon discharge, the proportions of patients prescribed antithrombotic, lipid-modulating, antidiabetic, and antihypertensive medications increased from CNSR I to CNSR III (p < 0.0001 for all; Figure 1).

Table 1.

Baseline characteristics of the study population.

Characteristics	No. (%) of patients from CNSR I (n = 12,873)	No. (%) of patients from CNSR III (n = 15,099)	p Value
Age^a	67 (57, 75)	63 (54, 70)	<0.0001
Men	7917 (61.50)	10,311 (68.29)	<0.0001
Days from onset to admission^a	1 (0, 2)	1 (0, 2)	<0.0001
NIHSS score at admission^a	4 (2, 9)	3 (1, 6)	<0.0001
Diagnosis			<0.0001
Ischemic stroke	11,757 (91.33)	14,083 (93.27)
TOAST			<0.0001
Large-artery atherosclerosis	5255 (44.70)	3649 (25.91)
Cardioembolism	1992 (16.94)	878 (6.23)
Small artery occlusion	734 (6.24)	3125 (22.19)
Other determined etiology	129 (1.10)	169 (1.20)
Undetermined etiology	3647 (31.02)	6262 (44.47)
TIA	1116 (8.67)	1016 (6.73)
Intravenous thrombolysis	444 (3.45)	1520 (10.07)	<0.0001
Endovascular therapy	25 (0.19)	93 (0.62)	<0.0001
Higher family income per capita^b	4162 (32.33)	8941 (59.22)	NA
Smoking	5089 (39.53)	7285 (48.25)	<0.0001
Alcohol consumption	3443 (26.75)	6763 (44.79)	<0.0001
History of stroke	4039 (31.38)	3334 (22.08)	<0.0001
History of TIA	652 (5.06)	414 (2.74)	<0.0001
History of dyslipidemia	1464 (11.37)	1184 (7.84)	<0.0001
History of diabetes	2712 (21.07)	3486 (23.09)	<0.0001
History of hypertension	8143 (63.26)	9456 (62.63)	0.2771
History of heart disease	870 (6.76)	2112 (13.99)	<0.0001

Median with interquartile range.

Family income per capita >3000 CNY for CNSR I and >2300 CNY for CNSR III monthly.

CNSR, China National Stroke Registry; CNY, Chinese yuan; NA, not applicable; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

Figure 1.

Prescription rate of secondary prevention medications at discharge.

Adherence and stroke recurrence rates

Over the 3-month period, patient adherence rates for secondary prevention medications increased from 66.97% in CNSR I to 80.76% in CNSR III (p < 0.0001), and over 12 months, these rates rose further from 35.08% to 59.81% (p < 0.0001). For specific medication categories, adherence rates also increased from CNSR I to CNSR III over both 3- and 12-month periods (Figure 2). Regarding stroke recurrence in CNSR I and III, the incidence rate decreased significantly from 12.68% to 5.86% over 3 months (p < 0.0001) and from 16.05% to 8.97% over 12 months (p < 0.0001).

Figure 2.

Patient adherence rate of secondary prevention medications in 3 and 12 months.

Influencing factor patterns of adherence in 3 months

The logistic regression analysis revealed that higher NIHSS score at admission (OR (95% CI) 1.011 (1.004, 1.019), p = 0.0017 in CNSR I; OR (95% CI) 1.021 (1.010, 1.033), p = 0.0003 in CNSR III), diagnosis of ischemic stroke (OR (95% CI) 1.626 (1.413, 1.870), p < 0.0010 in CNSR I; OR (95% CI) 1.322 (1.103, 1.585), p = 0.0026 in CNSR III), undetermined etiology (OR (95% CI) 1.263 (1.145, 1.393), p < 0.0001 in CNSR I; OR (95% CI) 0.793 (0.711, 0.884), p < 0.0001 in CNSR III; with reference to large artery atherosclerosis (LAA)), and higher family income per capita (OR (95% CI) 1.273 (1.170, 1.385), p < 0.0001 in CNSR I; OR (95% CI) 1.176 (1.082, 1.278), p = 0.0001 in CNSR III) were positively associated with 3-month medication adherence in both CNSR I and III. Moreover, previous diabetes and heart disease were negatively associated with medication adherence in CNSR I. Regarding CNSR III, older age, cardioembolism, and small artery occlusion were negatively associated with adherence. In the combined dataset, there were interactions of study period with the association of undetermined etiology with adherence (p < 0.0001; Figure 3). The sensitivity analysis yielded results that were comparable to the primary findings (Supplemental Figures 2 and 3).

Figure 3.

Factors influencing patient adherence to secondary prevention medications in 3 months.

Influencing factor patterns of adherence in 12 months

In 12 months, higher NIHSS score at admission (OR (95% CI) 1.021 (1.014, 1.029), p < 0.0001 in CNSR I; OR (95% CI) 1.015 (1.006, 1.025), p = 0.0009 in CNSR III), undetermined etiology (OR (95% CI) 1.812 (1.648, 1.992), p < 0.0001 in CNSR I; OR (95% CI) 0.899 (0.824, 0.979, p = 0.0149 in CNSR III; with reference to LAA), higher family income per capita (OR (95% CI) 1.430 (1.316, 1.554), p < 0.0001 in CNSR I; OR (95% CI) 1.127 (1.053, 1.206), p = 0.0006 in CNSR III), and a history of diabetes (OR (95% CI) 0.796 (0.719, 0.881), p < 0.0001 in CNSR I; OR (95% CI) 0.873 (0.805, 0.946), p = 0.0009 in CNSR III) were associated with medication adherence in both CNSR I and III. In addition, cardioembolism and a history of hypertension were statistically significantly associated with medication adherence in CNSR I. In CNSR III, small artery occlusion, alcohol consumption, and a history of dyslipidemia indicated a significant impact on patient adherence. In the combined dataset, significant interactions were observed between the study period and the relationship of ischemic stroke diagnosis and undetermined etiology with adherence (p < 0.0001 for both; Figure 4). The sensitivity analyses reported results that were similar to the main findings (Supplemental Figures 4 and 5).

Figure 4.

Factors influencing patient adherence to secondary prevention medications in 12 months.

The impact of influencing factors on adherence by medication categories

Patient age significantly influenced adherence to antithrombotic and antihypertensive medications. Higher NIHSS score at admission was associated with adherence to antithrombotic, lipid-modulating, and antihypertensive medications. Also, diagnosis of ischemic stroke and alcohol consumption history significantly influenced adherence to antithrombotic and lipid-modulating medications. The history of dyslipidemia, diabetes, and hypertension was associated with adherence to corresponding secondary prevention drug categories. Moreover, a significant impact of TOAST classification and higher family income per capita on adherence to all four medication categories was observed (Supplemental Tables 1 and 2).

Discussion

Focusing on secondary prevention medication adherence and its determinants among Chinese patients with ischemic stroke or TIA, this observational study encompassed a series of progressively analyses: Initially, to evaluate the effectiveness of healthcare quality improvement efforts spanning from 2007 to 2018, we examined patient adherence to secondary prevention medications and the recurrence rates of stroke during the periods of 2007–2008 (CNSR I) and 2015–2018 (CNSR III). Subsequently, we explored the potential factors influencing medication adherence at both 3- and 12-month intervals, with the aim of pinpointing areas for potential enhancement strategies. Finally, we conducted a detailed examination of how statistically significant influencing factors impact adherence to specific medication categories. Based on these insights, we outlined key priorities for enhancing future clinical practice and shaping health policy.

Over the decade spanning from 2007–2008 to 2015–2018, China witnessed a substantial increase in patient adherence to pharmacological interventions for the secondary prevention of stroke. This encouraging progression can most likely be attributed to several pivotal factors. First, the continuous improvement in healthcare quality may have positively influenced patients’ awareness regarding treatment adherence, driven by effective measures implemented by healthcare institutions.^14,19,28,29 Second, the revision of clinical practice guidelines, particularly the heightened emphasis on the paramount significance of secondary prevention, has profoundly influenced medical practice and patient engagement.^6,30 Third, the advancement of news media, coupled with its increased focus on popular science of health regarding stroke, has significantly contributed to raising public awareness of health issues.³¹ Last, the advancement of socioeconomic conditions and the effective execution of national pharmaceutical policies through these years, which have significantly improved medication accessibility and affordability, has likely contributed to this advancement as well.^32,33

Regarding influencing factors of adherence, the severity of illness, as indicated by the NIHSS score at admission, predominantly affects patient adherence to antithrombotic and lipid-modulating medications, which was similar to a previous study.³⁴ Patients with milder strokes, as evidenced by lower NIHSS scores, may underestimate the long-term risks linked to their condition and the significance of secondary prevention measures.³⁵ This underscores the necessity for healthcare professionals to prioritize patient education, particularly for those with milder conditions.³⁶ Furthermore, tailored follow-up plans and reminder systems can further ensure patients with mild stroke or TIA adhere to their treatment, boosting overall adherence and improving long-term health outcomes.³⁷ Regarding the TOAST classification, despite the presence of certain findings with statistical significance, clinical experience fails to provide support. This discrepancy may potentially be attributed to the distribution of sample sizes. Hence, large-scale studies in the future are warranted to further delve into the association between the TOAST classification and adherence to secondary prevention medications.

The significant impact of disease diagnosis on medication adherence in 2007–2008, but not in 2015–2018, mirrors the evolving landscape of stroke prevention and management. During the earlier period, there might have been a lack of sufficient awareness and consensus concerning the optimal utilization of secondary prevention medications for various stroke-related diagnoses.³⁸ However, with advancements in scientific research and clinical practice, both healthcare professionals and patients developed a heightened awareness of the significance of secondary prevention medications to TIA patients, which probably played a role in reducing the impact of disease diagnosis on medication adherence during the subsequent period.^39–41 However, it remains imperative to persistently monitor and guarantee that every patient with stroke-related diagnoses, encompassing TIA, receives appropriate secondary prevention care.⁴²

Family per capita income consistently stands out as a key factor that significantly influences patient adherence, especially to lipid-modulating and antihypertensive drugs. From the patients’ perspective, financial limitations can restrict their capacity to afford these typically long-term medications, even when they are aware of their crucial role in preventing secondary health issues.⁴³ Therefore, healthcare providers could deliver more tailored counseling on the long-term cost-effectiveness of these medications, and highlight how consistent use can prevent more costly and debilitating health problems down the line.⁴⁴ Furthermore, this finding calls for initiatives to enhance medication accessibility for low-income populations. Despite continuous reform and optimization of pharmaceutical policies, which have significantly improved drug accessibility and affordability, economic challenges still persist.⁴⁵ Governments might consider providing subsidies for these essential secondary preventive medications or incorporating them into public health initiatives.³² In addition, efforts to increase public awareness about the importance of these medications should be stepped up, particularly in economically disadvantaged areas.⁴⁶

The significant negative correlation between alcohol consumption and secondary prevention medication adherence in 2015–2018 was a concerning finding. Alcohol consumption can have multiple detrimental effects on health, and in the context of stroke prevention, it may interfere with patients’ ability to adhere to their medication regimens.⁴⁷ Patients with alcohol use may face challenges such as forgetfulness, lack of motivation, or competing priorities related to their alcohol use, which can lead to missed doses or complete nonadherence to secondary prevention drugs.⁴⁸ Healthcare providers should assess the extent of alcohol consumption and its potential impact on the patient’s lifestyle and treatment plan.⁴⁹ This could involve developing tailored strategies to address specific barriers to adherence, such as setting up reminder systems, providing education on the interaction between alcohol and medications, and offering support for alcohol cessation or reduction.⁴⁷

This study revealed a complex and dynamic relationship between patients’ medical history and their adherence to secondary prevention medications over time. A history of dyslipidemia was positively associated with secondary prevention adherence from 2015 to 2018. Further analysis demonstrated a negative association with lipid-modulating medication adherence in 2007–2008 but a positive association in 2015–2018. A previous study also reported similar findings.³⁴ This shift indicates that lipid control treatment has garnered wider attention in patients with a history of dyslipidemia and has achieved notable success.⁵⁰ However, for patients without a history of dyslipidemia, attention needs to be paid to enhancing their adherence to lipid-modulating medications. By contrast, during both the 2007–2008 and 2015–2018 periods, a history of diabetes exhibited a negative correlation with adherence to secondary prevention medications and antidiabetic medications. This seems to imply that we ought to show more concern for and come up with more strategies to improve the secondary prevention adherence of patients who have a history of diabetes. Also, these results highlight the persistent challenges in attaining optimal medication adherence for blood glucose management.⁹ Moreover, healthcare system-related factors, such as restricted access to affordable medications, insufficient follow-up care, and inadequate patient education initiatives, could also contribute to the suboptimal adherence rates.¹³

Beyond patient-related factors, a range of strategies can be implemented to bolster patient adherence. At the healthcare facility level, this entails setting up dedicated stroke follow-up clinics or secondary prevention management centers, creating individualized patient profiles tailored to secondary prevention needs, and assembling a multidisciplinary team comprising neurologists, pharmacists, nurses, rehabilitation specialists, and other experts for comprehensive patient care.⁵¹ On the community front, initiatives such as organizing community health education campaigns, establishing a structured community follow-up network, and facilitating patient support groups can play a pivotal role.⁵² From a policy perspective, enhancing medical insurance reimbursement rates or introducing dedicated funds, instituting medication adherence assessment metrics, and tightening regulations on drug effectiveness and safety are crucial steps.^45,53 In the realm of technological innovation, the development of intelligent medication reminder applications and the widespread adoption of electronic prescription and medication delivery services hold significant promise.

This study bears several limitations that warrant consideration. First, the analysis centers on the general landscape and deficiencies in accordance with the guideline recommendations, rather than delving into the specifics of individual patient cases. It is plausible that certain patients may no longer necessitate particular medications due to evolving medical conditions or re-assessments, data for which was not captured. Nonetheless, this limitation does not compromise our findings. Second, baseline characteristics differed between patients from CNSR I and CNSR III. However, we controlled for these variables, data sources, and their interactions in the analysis. Third, the datasets from the two registries lack information concerning the underlying reasons for patient non-adherence. Consequently, future research endeavors should explore this facet to attain a more comprehensive understanding of the issue. Fourth, deceased patients were excluded due to the unavailability of their adherence information, consequently resulting in failing to account for the impact of non-adherence on mortality and the increased likelihood of non-adherence among patients with more severe conditions. Future studies should delve into the association between patient adherence and mortality, taking potential covariates into account.

Conclusion

From 2007 to 2018, a decade of quality improvement initiatives led to substantial improvements in patient adherence to secondary prevention of stroke, reflecting significant progress in healthcare quality of ischemic stroke and TIA. However, patient medication adherence remains suboptimal and requires further improvement, particularly by accounting for factors such as disease severity, lifestyle, medical history, and socioeconomic status. Looking ahead, sustaining healthcare quality improvement demands ongoing commitment, innovation, and collaboration from policymakers, healthcare professionals, and patients across the healthcare ecosystem.

Supplemental Material

sj-docx-1-tan-10.1177_17562864251406061 – Supplemental material for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018

Supplemental material, sj-docx-1-tan-10.1177_17562864251406061 for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018 by Yuan Shen, Xinya Li, Xue Xia, Meng Gao, Xue Tian, Qin Xu, Xiaoli Zhang, Ruobing Tian, Xia Meng and Anxin Wang in Therapeutic Advances in Neurological Disorders

Supplemental Material

sj-docx-2-tan-10.1177_17562864251406061 – Supplemental material for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018

Supplemental material, sj-docx-2-tan-10.1177_17562864251406061 for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018 by Yuan Shen, Xinya Li, Xue Xia, Meng Gao, Xue Tian, Qin Xu, Xiaoli Zhang, Ruobing Tian, Xia Meng and Anxin Wang in Therapeutic Advances in Neurological Disorders

Footnotes

Acknowledgements

We thank all the investigators at each site, as well as all participants.

Declarations

ORCID iDs

Xinya Li

Anxin Wang

Supplemental material

Supplemental material for this article is available online.

References

Hilkens

Casolla

Leung

, et al. Stroke. Lancet 2024; 403(10446): 2820–2836.

Walter

What is acute ischemic stroke?

JAMA 2022; 327(9): 885.

GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23(10): 973–1003.

Lioutas

Ivan

Himali

, et al. Incidence of transient ischemic attack and association with long-term risk of stroke. JAMA 2021; 325(4): 373–381.

Amin

Madsen

Bravata

, et al. Diagnosis, workup, risk reduction of transient ischemic attack in the emergency department setting: a scientific statement from the American Heart Association. Stroke 2023; 54(3): e109–e121.

Mead

Sposato

Sampaio Silva

, et al. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke 2023; 18(5): 499–531.

Liu

Zhou

, et al. Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update. Stroke Vasc Neurol 2023; 8(6): e3.

Mendelson

Prabhakaran

Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review. JAMA 2021; 325(11): 1088–1098.

Kleindorfer

Towfighi

Chaturvedi

, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52(7): e364–e467.

10.

Turc

Bhogal

Fischer

, et al. European Stroke Organisation (ESO)—European society for minimally invasive neurological therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg 2023; 15(8): e8.

11.

Mansoor

Manion

Kucharska-Newton

, et al. Sex differences in prescription patterns and medication adherence to guideline-directed medical therapy among patients with ischemic stroke. Stroke 2025; 56(2): 318–325.

12.

Murphy

Palafox

O’Donnell

, et al. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. Lancet Glob Health 2018; 6(3): e292–e301.

13.

Bangad

Abbasi

de Havenon

Secondary ischemic stroke prevention. Neurotherapeutics 2023; 20(3): 721–731.

14.

Xian

Jiang

, et al. Twenty years of sustained improvement in quality of care and outcomes for patients hospitalized with stroke or transient ischemic attack: data from the get with the guidelines-stroke program. Stroke 2024; 55(11): 2599–2610.

15.

Kronish

Diefenbach

Edmondson

, et al. Key barriers to medication adherence in survivors of strokes and transient ischemic attacks. J Gen Intern Med 2013; 28(5): 675–682.

16.

Wang

Zhao

, et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China: a randomized clinical trial. JAMA 2018; 320(3): 245–254.

17.

Wang

C-J

H-Q

Zong

L-X

, et al. Effectiveness of a quality improvement intervention on reperfusion treatment for patients with acute ischemic stroke: a stepped-wedge cluster randomized clinical trial. JAMA Netw Open 2023; 6(6): e2316465.

18.

Wang

Zhao

, et al. Stroke care quality in China: substantial improvement, and a huge challenge and opportunity. Int J Stroke 2017; 12(3): 229–235.

19.

Zhang

Jin

, et al. Trends and risk factors associated with stroke recurrence in China, 2007–2018. JAMA Netw Open 2022; 5(6): e2216341.

20.

Yin

Meng

, et al. Trends in care quality in China from 2011 to 2017: an analysis based on the national specific (single) disease monitoring system. J Glob Health 2023; 13: 04045.

21.

Wang

Jing

Meng

, et al. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke Vasc Neurol 2019; 4(3): 158–164.

22.

Wang

Cui

, et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011; 6(4): 355–361.

23.

Stroke—1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20(10): 1407–1431.

24.

Boutron

Altman

Moher

, et al. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med 2017; 167(1): 40–47.

25.

H-Q

Yang

Wang

C-J

, et al. Clinical characteristics, management, and in-hospital outcomes in patients with stroke or transient ischemic attack in China. JAMA Netw Open 2021; 4(8): e2120745.

26.

Greco

Occhipinti

Giacoppo

, et al. Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC state-of-the-art review. J Am Coll Cardiol 2023; 82(15): 1538–1557.

27.

Sposato

Albin

Elkind

MSV

, et al. Patent foramen ovale management for secondary stroke prevention: state-of-the-art appraisal of current evidence. Stroke 2024; 55(1): 236–247.

28.

Chao

Yan

Hua

, et al. Stroke prevention and control system in China: CSPPC-Stroke Program. Int J Stroke 2021; 16(3): 265–272.

29.

Liu

Wang

, et al. Substantial improvement of stroke care in China. Stroke 2018; 49(12): 3085–3091.

30.

Campbell

BC.

Hyperacute ischemic stroke care—current treatment and future directions. Int J Stroke 2024; 19(7): 718–726.

31.

Appalasamy

Joseph

Seeta Ramaiah

, et al. An intervention to promote medication understanding and use self-efficacy: design of video narratives for aging patients at risk of recurrent stroke. JMIR Aging 2019; 2(1): e11539.

32.

Mao

Jiang

Mossialos

, et al. Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020. BMJ Glob Health 2022; 7(11): e009916.

33.

Jiang

Zhao

Jia

, et al. Trends of drug licensing in China: from bring-in to go-global. Pharmacol Res 2024; 210: 107488.

34.

Jiang

Yang

, et al. Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China. Neurol Res 2017; 39(6): 492–497.

35.

Downer

Luengo-Fernandez

Binney

, et al. Association of multimorbidity with mortality after stroke stratified by age, severity, etiology, and prior disability. Int J Stroke 2024; 19(3): 348–358.

36.

Marto

Qureshi

Nagel

, et al. Endovascular therapy for patients with low NIHSS scores and large vessel occlusion in the 6- to 24-hour window: analysis of the CLEAR study. Neurology 2025; 104(7): e213442.

37.

Liv

Lundström

, et al. Study protocol for a randomized, controlled, multicentre, pragmatic trial with Rehabkompassen^®—a digital structured follow-up tool for facilitating patient-tailored rehabilitation in persons after stroke. Trials 2023; 24(1): 650.

38.

Saini

Guada

Yavagal

DR.

Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology 2021; 97(20 Suppl. 2): S6–S16.

39.

Easton

Johnston

SC.

Time to retire the concept of transient ischemic attack. JAMA 2022; 327(9): 813–814.

40.

Fonseca

Merwick

Dennis

, et al. European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. Eur Stroke J 2021; 6(2): Clxiii–Clxxxvi.

41.

Mbonde

O’Carroll

Dulamea

, et al. Current guidelines on management of Amaurosis Fugax and transient ischemic attacks. Asia Pac J Ophthalmol (Phila) 2022; 11(2): 168–176.

42.

Kirshner

HS.

The concept of transient ischemic attack. JAMA 2022; 327(24): 2456–2457.

43.

Spees

Wheeler

Zhou

, et al. Changes in chronic medication adherence, costs, and health care use after a cancer diagnosis among low-income patients and the role of patient-centered medical homes. Cancer 2020; 126(21): 4770–4779.

44.

Lin

Moran

Bibbins-Domingo

, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health 2019; 7(10): e1346–e1358.

45.

Zhang

Wang

Yao

, et al. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis. Int J Equity Health 2024; 23(1): 116.

46.

Yan

Gong

, et al. Effectiveness of a primary care-based integrated mobile health intervention for stroke management in rural China (SINEMA): a cluster-randomized controlled trial. PLoS Med 2021; 18(4): e1003582.

47.

Lee

S-R

Choi

E-K

Jung

J-H

, et al. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. Eur Heart J 2021; 42(46): 4759–4768.

48.

Kuhns

Kroon

Lesscher

, et al. Age-related differences in the effect of chronic alcohol on cognition and the brain: a systematic review. Transl Psychiatry 2022; 12(1): 345.

49.

Menkes

DB.

Pharmacological interactions: more reason to regard alcohol as a drug. BMJ 2018; 363: k4952.

50.

Ugusman

Hisam

NSN

Othman

, et al. Pharmacological interventions for intraplaque neovascularization in atherosclerosis. Pharmacol Ther 2024; 261: 108685.

51.

Sakakibara

Lear

Barr

, et al. Telehealth coaching to improve self-management for secondary prevention after stroke: a randomized controlled trial of Stroke Coach. Int J Stroke 2022; 17(4): 455–464.

52.

Wakefield

Loken

Hornik

RC.

Use of mass media campaigns to change health behaviour. Lancet 2010; 376(9748): 1261–1271.

53.

Ágh

Hiligsmann

Borah

, et al. Systematic review of outcomes for assessment of medication adherence enhancing interventions: an ISPOR special interest group report. Value Health 2024; 27(2): 133–142.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.80 MB

0.03 MB

Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China,2007–2018

Abstract

Background:

Objectives:

Design:

Methods:

Results:

Conclusion:

Keywords

Introduction

Methods

Data source and study population

Outcomes

Variables

Statistical analysis

Results

Baseline characteristics

Adherence and stroke recurrence rates

Influencing factor patterns of adherence in 3 months

Influencing factor patterns of adherence in 12 months

The impact of influencing factors on adherence by medication categories

Discussion

Conclusion

Supplemental Material

sj-docx-1-tan-10.1177_17562864251406061 – Supplemental material for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018

Supplemental Material

sj-docx-2-tan-10.1177_17562864251406061 – Supplemental material for Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007–2018

Footnotes

Acknowledgements

Declarations

ORCID iDs

Supplemental material

References

Supplementary Material